Search

Displaying results 1931 - 1940 of 4589 in total
  1. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI)
  2. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  3. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [L7895] Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors.

  4. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

  5. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects).

  6. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).

  7. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  8. Drug

    Metharbital

    go.drugbank.com/drugs/DB00463
    ApprovedWithdrawn

    Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.

  9. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

  10. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water.